Study to evaluate the pharmacokinetics, safety and tolerability of Secukinumab in patients with GCA or PMR

2023-507667-19-00 Protocol CAIN457E22101 Human pharmacology (Phase I) - Other Ended

Start 6 Jun 2024 · End 3 Apr 2025 · Status Ended · 4 EU/EEA countries · 11 sites · Protocol CAIN457E22101

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 62
Countries 4
Sites 11

Polymyalgia rheumatica (PMR)

Key facts

Sponsor
Novartis Pharma AG
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Musculoskeletal Diseases [C05]
Trial duration
6 Jun 2024 → 3 Apr 2025
Decision date (initial)
2024-05-03
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-507667-19-00
ClinicalTrials.gov
NCT06130540

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Polymyalgia rheumatica (PMR)

VersionLevelCodeTermSystem organ class
20.0 SOC 10028395 Musculoskeletal and connective tissue disorders 17
23.1 PT 10018250 Giant cell arteritis 10047065

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Novartis Pharma AG

Sponsor organisation
Novartis Pharma AG
Address
Lichtstrasse 35
City
Basel Town
Postcode
4056
Country
Switzerland

Scientific contact point

Organisation
Novartis Pharma AG
Contact name
Novartis Pharma Arzneimittel GmbH

Public contact point

Organisation
Novartis Pharma AG
Contact name
Novartis Pharma Arzneimittel GmbH

Locations

4 EU/EEA countries · 11 investigational sites

By country

CountryMS statusPlanned subjectsSites
Czechia Ended 4 3
Italy Ended 10 4
Portugal Ended 4 1
Spain Ended 6 3
Rest of world
United States, Switzerland
38

Investigational sites

Czechia

3 sites · Ended
Fakultni Nemocnice Brno
2001: Revmatologická ambulance, Jihlavska 340/20, Bohunice, Brno
Revmacentrum MUDr. Mostera s.r.o.
#2004 : Revmatologie, Mosnova 2476/8, Zidenice, Brno-Zidenice
Medical Plus s.r.o.
#2003: Revmatologie, Obchodni 1507, 686 01, Uherske Hradiste

Italy

4 sites · Ended
Azienda USL IRCCS Di Reggio Emilia
2051:U. O. Reumatologia, Viale Risorgimento 80, 42123, Reggio Emilia
Centro Ricerche Cliniche Di Verona S.r.l.
2053: U.O.C. di Reumatologia, Piazzale Ludovico Antonio Scuro 10, 37134, Verona
Careggi University Hospital
2052:S. O.D. Reumatologia, Largo Giovanni Alessandro Brambilla 3, 50134, Florence
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
2054:Unità di Fase I - FI/112, Piazzale Spedali Civili 1, 25123, Brescia

Portugal

1 site · Ended
Unidade Local De Saude De Santa Maria E.P.E.
2101: Serviço de Reumatologia, Avenida Professor Egas Moniz, 1649-035, Lisbon

Spain

3 sites · Ended
Hospital General Universitario Gregorio Maranon
2154: Rheumatology Department, Calle Del Doctor Esquerdo 46, 28009, Madrid
Hospital Universitario La Paz
2151: Rheumatology Department, Paseo Castellana 261, 28046, Madrid
Complexo Hospitalario Universitario De Santiago
2152 : Rheumatology Department, Calle Choupana Da S/n, 15706, Santiago De Compostela

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Czechia 2024-10-09 2025-02-11 2024-10-09 2024-12-18
Italy 2024-09-11 2025-01-14 2024-09-11 2024-12-18
Portugal 2024-07-01 2025-02-25 2024-07-01 2024-12-18
Spain 2024-06-06 2025-04-02 2024-06-06 2024-12-18

Application history

7 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-01-15 Czechia Acceptable with conditions
2024-05-03
2024-05-03
2 NON SUBSTANTIAL MODIFICATION NSM-1 2024-06-14 Czechia Acceptable with conditions
2024-05-03
2024-06-14
3 NON SUBSTANTIAL MODIFICATION NSM-2 2024-06-21 Acceptable with conditions
2024-05-03
2024-06-21
4 SUBSTANTIAL MODIFICATION SM-2 2024-06-25 Acceptable with conditions 2024-08-09
5 SUBSTANTIAL MODIFICATION SM-3 2024-06-27 Czechia Acceptable with conditions 2024-08-30
6 SUBSTANTIAL MODIFICATION SM-4 2024-11-18 Czechia Acceptable
2025-01-30
2025-01-30
7 NON SUBSTANTIAL MODIFICATION NSM-3 2025-02-14 Czechia Acceptable
2025-01-30
2025-02-14